Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 - TACC3||Advanced Solid Tumor||sensitive||AZD4547||Phase II||Actionable||In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 56%, including partial responses in 2 patients and stable disease for greater than 6 months in 1 of 8 patients harboring FGFR3-TACC3 (PMID: 32463741; NCT02465060).||32463741|
|FGFR3 - TACC3||Advanced Solid Tumor||sensitive||AZD4547||Preclinical - Cell culture||Actionable||In a preclinical study, AZD4547 inhibited proliferation of transformed cells expressing FGFR3-TACC3 in culture (PMID: 26992226).||26992226|
|PubMed Id||Reference Title||Details|
|(26992226)||Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.||Full reference...|
|(32463741)||Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.||Full reference...|